EIPICO
- Company typePublic
- Founded1980
- HeadquartersTenth Of Ramadan City, Egypt
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
EIPICO firmographics
Firmographics- Name
- EIPICO
- Legal name
- Egyptian International Pharmaceutical Industries Company
- Website
- https://eipico.com.eg
- Company type
- Public
- Founded year
- 1980
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Ownership category
- akta.pro rank
EIPICO industry classification
Industry- Product category
- Pharmaceutical Manufacturing
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Biological Products, (No Disgnostic Substances) (2836), Ophthalmic Goods (3851)
- akta.pro primary industry
- Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules) (IMALAIAA)
- akta.pro secondary industries
- Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes) (IMALAEAB), Rigid Pharmaceutical & Healthcare Plastic Packaging (Pill Bottles, Vials, Med-Grade Jars) (IMALAAAE), Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers) (IMALAIAB), Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)
Keywords
Where EIPICO is headquartered
LocationHeadquarters
- HQ city
- Tenth Of Ramadan City
- HQ country
- Egypt
- HQ region
- Africa
Offices9 records
Markets served
EIPICO business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Others
Revenue model
- Pharmaceutical Products Sales - Domestic: Sale of over 400 pharmaceutical products covering 25 therapeutic classes to the Egyptian market through pharmacies and hospitals. Products include antibiotics, antivirals, ophthalmics, cardiovascular drugs, and more.
- Pharmaceutical Products Export: Export of pharmaceutical products to 67 countries worldwide. EIPICO holds license agreements with international pharmaceutical companies to produce their products locally. Also exports semi-finished contract manufacturing products.
- Contract Manufacturing: Semi-finished and finished product manufacturing under license agreements with multinational pharmaceutical companies. Manufacturing for Batterjee Pharma in Saudi Arabia (30% owned joint venture).
- Primary Packaging Materials: EIACO affiliate manufactures and sells primary packaging materials including ampoules, vials, and aluminum tubes to other pharmaceutical companies in Egypt.
Go-to-market motion2 records
Distribution channels7 records
Marketing channels6 records
EIPICO product offering
Product offeringCore offering
EIPICO manufactures and markets over 400 pharmaceutical products across 25 therapeutic classes (antibiotics, antivirals, ophthalmics, cardiovascular, respiratory, gastrointestinal, dermatological, analgesics, corticosteroids, biosimilars) from facilities in Tenth of Ramadan City, Egypt. The company also performs contract manufacturing under license for international pharmaceutical companies, produces primary packaging materials (ampoules, vials, dropper bottles) through its EIACO and Plastic Factory affiliates, and exports to 67+ countries.
Product overview
EIPICO (Egyptian International Pharmaceutical Industries) is a leading Egyptian pharmaceutical company manufacturing over 400 pharmaceutical products across 25+ therapeutic classes. The product portfolio spans antibiotics (including cephalosporins, penicillins, fluoroquinolones), analgesics/antipyretics (paracetamol products), cardiovascular medications, respiratory treatments, ophthalmic products, dermatological products, gastrointestinal medications, antihistamines, corticosteroids, and biologicals/biosimilars. Key product lines include: Cetal (paracetamol) line with tablets, caplets, oral suspension, drops, and suppositories; E-MOX (amoxicillin) antibiotics; BRONCHOLIN respiratory products; DEXATOBRIN ophthalmic solutions; and the newly launched ADALIMAB biosimilar from EIPICO 3 facility. The company operates manufacturing facilities including Factory 1 (established 1980), Factory 2 (2013), EIPICO 3 (biologicals/biosimilars), Plastic Factory, and affiliate EIACO for primary packaging materials.
Differentiator
Problem solved
Functional benefit
Brands
- Episovir: Anti-viral product used in Egypt 2030 with No Virus-C initiative, provided free to Egyptian public hospitals
- EIPICO 3
- EPIC
- E-CPD
Quantifiable outcome
- 26% of Egypt's total pharmaceutical exports
- +5 more outcomes
Companies that use EIPICO
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles3 records
EIPICO technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature5 records
EIPICO partnerships and signals
Strategic signalPartnerships
Eleven partnerships are on record, tiered core and key.
- Unified Procurement Agency (Egypt)coreADALIMAB biosimilar awarded to be supplied to Unified Procurement Agency to ensure availability to large segment of patients.
- Al Dana Medical Company (Qatar)keyStrategic partnership agreement signed in Doha for marketing and distribution of EIPICO's pharmaceutical products in Qatar. Al Dana Medical Company has extensive experience and strong relationships in Qatar's healthcare sector.
- Propharma Distribution Company (Uzbekistan)keyAgreement signed for Propharma to distribute EIPICO's products in Uzbekistan. Part of efforts to increase exports and enhance presence in Uzbekistan and neighboring countries.
- LAFZ Pharmaceuticals (Uzbekistan)keyMOU signed allowing ACDIMA's companies to manufacture their products at LAFZ's factory in Tashkent, Uzbekistan.
- Reliance Life Sciences (India)coreIndian biotechnology company providing technology and expertise for biosimilar manufacturing. EIPICO 3 factory utilizes process standards set by Reliance Life Science for manufacturing monoclonal antibodies and recombinant protein products.
- Supreme Council of University HospitalskeyCooperation agreement signed to support national institutional identity of university hospitals, enhance programs for developing capabilities of healthcare providers including doctors, pharmacists, and nurses in university hospitals.
- ARAB API (Arab Company for Active Pharmaceutical Ingredients)coreJoint venture for establishing first multi-purpose factory in Egypt and Middle East for pharmaceutical raw materials. Contributions: ACDIMA 60%, EIPICO 30%, SCZONE Investment Company 10%. Land of 96,828 sqm in Ain Sokhna. Investments of USD 165 million.
- German International University (GIU)coreMOU signed for academic and industry collaboration to promote education needs, job market requirements, and real opportunity for students to practice sciences. Training programs set for students of Faculties of Pharmaceutical Engineering and Biotechnology lasting five consecutive months.
- Kazakhstan Government (Ministry of Health, Kazakhstan Invest, QIC)keyDiscussions for implementing Egy Kazakh Pharmaceutical Park in Kazakhstan with investments up to 33 million USD, providing 200 job opportunities. Kazakh city of Almaty chosen for factory establishment to localize pharmaceutical industry in Kazakhstan.
- Pharmadule Morimatsu AB (Sweden)coreSwedish company that designed and fabricated prefabricated modular structure building techniques for EIPICO 3 biological and biosimilar facility. Modules were designed and equipped abroad, shipped to Egypt, and installed. EIPICO applied this construction concept to ensure highest standards and guarantee performance efficacy.
- Batterjee Pharma (Saudi Arabia)coreEIPICO owns 30% stake in Batterjee Pharma joint venture established in Saudi Arabia. First EIPICO investment abroad in manufacturing pharmaceutical products. Started production in 2009 in Jeddah Industrial Zone Phase IV, manufacturing 30 products exported to Bahrain, UAE, and Yemen.
Scale indicators21 records
Recent moves10 records
Expansion highlights6 records
EIPICO competitors and assessment
Company assessmentBroad incumbents
- Cipla: Indian-headquartered global generic manufacturer with strong MENA and African presence. Comparable in generic antibiotics, antiretrovirals, and biosimilars, and competes with EIPICO in African and CIS export markets.
- Aurobindo Pharma: Large Indian generic manufacturer with significant MENA, African, and European export business. Comparable in injectable and oral generic product portfolio competing for the same regional tenders as EIPICO.
- Hikma Pharmaceuticals: Jordan-headquartered multinational generics and injectables manufacturer with extensive MENA presence. Comparable to EIPICO in therapeutic categories (antibiotics, injectables) and geographic reach, though at substantially larger scale.
Direct peers
- Eva Pharma: Major Egyptian pharmaceutical manufacturer with broad generic portfolio and growing biosimilars and exports business. Directly comparable to EIPICO as a fellow top-tier Egyptian pharma with antibiotic, ophthalmic, and biosimilar exposure targeting MENA/Africa.
- Julphar (Gulf Pharmaceutical Industries): UAE-based generics and biosimilars manufacturer serving MENA. Competes with EIPICO in regional tenders and biosimilar pipelines, with similar regulatory certification profile (EU GMP, WHO PQ).
- Tabuk Pharmaceuticals: Saudi pharmaceutical manufacturer with branded generics, biologics, and biosimilars. Comparable to EIPICO in product mix, regional export ambitions, and biosimilar strategy targeting MENA markets.
- SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances): Saudi-listed pharmaceutical manufacturer producing generics and licensed products for the Saudi/GCC market. Directly comparable as a regional pharma peer with similar product breadth, regulatory certifications, and MENA distribution model.
- Pharco Pharmaceuticals: Largest Egyptian pharmaceutical manufacturer by some measures, focused on generics, antibiotics, and hepatitis treatments. Competes head-to-head with EIPICO in the Egyptian market and across export markets, including biosimilars.
- Medical Union Pharmaceuticals (MUP): Egyptian pharmaceutical company in which EIPICO holds a 10% stake (acquired 2020). Direct peer as a fellow Egyptian pharma manufacturer; EIPICO's investment also signals strategic overlap and partnership potential.
Regional players
- Marcyrl Pharmaceutical Industries: Egyptian pharmaceutical manufacturer focused on generics, injectables, and biosimilars. Comparable in product categories and Egyptian-market positioning, with growing biosimilar pipeline similar to EIPICO 3.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
EIPICO social profiles
Digital presenceEIPICO compliance and trust
Trust signalCompliance22 records
EIPICO financial estimates
Financial estimateRevenue estimate
Valuation estimate
EIPICO leadership team
Management profileNumber of profiles
Profiles8 records
EIPICO subsidiaries and ownership
Company hierarchySubsidiaries5 records
EIPICO funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
EIPICO M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about EIPICO
What does EIPICO do?
EIPICO manufactures and markets over 400 pharmaceutical products across 25 therapeutic classes (antibiotics, antivirals, ophthalmics, cardiovascular, respiratory, gastrointestinal, dermatological, analgesics, corticosteroids, biosimilars) from facilities in Tenth of Ramadan City, Egypt. The company also performs contract manufacturing under license for international pharmaceutical companies, produces primary packaging materials (ampoules, vials, dropper bottles) through its EIACO and Plastic Factory affiliates, and exports to 67+ countries.
Is EIPICO a public or private company?
EIPICO is a public company. It is classified as public and is currently operating.
When was EIPICO founded?
EIPICO was founded in 1980. It employs 1,001 to 5,000 people.
Where is EIPICO based?
EIPICO is headquartered in Tenth Of Ramadan City, Egypt, in the Africa region.
How does EIPICO make money?
Four revenue lines are on record. Pharmaceutical Products Sales - Domestic is the primary driver. The others are pharmaceutical Products Export, contract Manufacturing and primary Packaging Materials.
Who are EIPICO's main competitors?
Broad incumbents on record are Cipla, Aurobindo Pharma and Hikma Pharmaceuticals. Direct peers are Eva Pharma, Julphar (Gulf Pharmaceutical Industries), Tabuk Pharmaceuticals, SPIMACO (Saudi Pharmaceutical Industries & Medical Appliances), Pharco Pharmaceuticals and Medical Union Pharmaceuticals (MUP). Marcyrl Pharmaceutical Industries is listed as a regional player.
Does EIPICO have an API?
No public API is recorded for EIPICO.
What industry is EIPICO in?
EIPICO's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is IMALAIAA, Primary Pharmaceutical Packaging (Blister Packs, Bottles, Vials, Ampoules), with a secondary code of IMALAEAB, Pharmaceutical & Medical Glass Packaging (Vials, Ampoules, Syringes). Its NAICS code is 325412 and its SIC code is 2834.